A randomised, double-blind, outpatient, crossover study of the anti-platelet effects of AZD6140 [ticagrelor] compared with clopidogrel in patients with stable coronary artery disease previously identified as clopidogrel non-responders or responders [RESPOND].

Trial Profile

A randomised, double-blind, outpatient, crossover study of the anti-platelet effects of AZD6140 [ticagrelor] compared with clopidogrel in patients with stable coronary artery disease previously identified as clopidogrel non-responders or responders [RESPOND].

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Acronyms RESPOND
  • Most Recent Events

    • 01 Mar 2010 Results were published online before print March 1 2010.
    • 18 Nov 2009 Results have been presented at the American Heart Association Scientific Sessions (AHA 2009), according to an AstraZeneca media release.
    • 01 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top